ImmuPharma plc (LON:IMM – Get Free Report)’s stock price was up 56% during trading on Monday . The company traded as high as GBX 7.14 ($0.09) and last traded at GBX 6.14 ($0.08). Approximately 39,645,953 shares changed hands during trading, an increase of 91% from the average daily volume of 20,792,326 shares. The stock had previously closed at GBX 3.94 ($0.05).
ImmuPharma Price Performance
The company’s fifty day simple moving average is GBX 1.75 and its 200-day simple moving average is GBX 1.73. The firm has a market capitalization of £24.99 million, a PE ratio of -600.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- What to Know About Investing in Penny Stocks
- Sizing Up a New Opportunity for NVIDIA Investors
- What is a Dividend King?
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- What does consumer price index measure?
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
